Last update 12 Dec 2024
Zamtocabtagene autoleucel
Last update 12 Dec 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms- |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators), CD20 modulators(B-lymphocyte antigen CD20 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with Zamtocabtagene autoleucelA Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory (r/r) Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease
A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects with Severe Refractory Autoimmune Diseases
100 Clinical Results associated with Zamtocabtagene autoleucel
Login to view more data
100 Translational Medicine associated with Zamtocabtagene autoleucel
Login to view more data
100 Patents (Medical) associated with Zamtocabtagene autoleucel
Login to view more data
1
Literatures (Medical) associated with Zamtocabtagene autoleucel01 Oct 2024RMD Open
Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel
Article
Author: Heteren, Pearl van ; Nagy, György ; Gopcsa, Laszlo ; Balogh, Alexandra ; Zadoyan, Gregor ; Giba-Kiss, Laura ; Takacs, Peter ; Reti, Marienn ; Remenyi, Peter ; Paksi, Melinda ; Miltenyi, Stefan ; Lakatos, Gergely ; Overstijns, Toon ; Holtkamp, Silke ; Szabo, David
We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
100 Deals associated with Zamtocabtagene autoleucel
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Refractory Mature B-Cell Non-Hodgkin Lymphoma | Phase 2 | - |  Miltenyi Biomedicine GmbHStartup | 01 Apr 2025 |
| Lupus Nephritis | Phase 1 | - | Miltenyi Biomedicine GmbHStartup | 01 Jan 2025 |
| Scleroderma, Diffuse | Phase 1 | - | Miltenyi Biomedicine GmbHStartup | 01 Jan 2025 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free